Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Seiichi Kobayashi

William J Christ

Shinya Abe

Hiroyuki Yoshimura

Mitsuo Nagai

Isao Yamatsu

Toshihiko Kaneko

Jean-Christophe P Harmange

Makoto Okita

Kouichi Kikuchi

Tsutomu Kawata

Daniel P Rossignol

Osamu Asano

Takayuki Hida

Shigeki Hibi

Katsuya Tagami

Manabu Murakami

Motohiro Soejima

Lynn D Hawkins

Hitoshi Harada

Takeshi Suzuki

Mark Spyvee

Yasushi Okamoto

Mitsuaki Miyamoto

Yuichi Inai

Kenzo Muramoto

Takashi Sato

Ieharu Hishinuma

Boris M Seletsky

Yimin Jiang

Wanjun Zheng

Yorihisa Hoshino

Shuhei Miyazawa

Shigeto Negi

Naoyuki Shimomura

Isao Tanaka

Takashi Inoue

Heather Davis

Hironori Ikuta

Hisashi Shibata

Yoshihiko Kotake

Kenji Hayashi

Nobuhisa Watanabe

Kouichi Katayama

Satoshi Yamamoto

Tomohiro Matsushima

Naoki Yoneda

Roch Boivin

Kozo Akasaka

Youji Yamagishi

Atsushi Inoue

Toshihiko Naito

Makoto Kotake

Naoki Tokuhara

Nobuyuki Yasuda

Seiko Higashi

Kokichi Harada

Tatsuya Yoshiuchi

André Lescarbeau

Junsaku Nagaoka

Norihito Ohi

Seiji Yoshikawa

Tatsuo Horizoe

Naoki Kobayashi

Xiang-Yi Li

Masayuki Tanaka

Kenji Tai

Kouzi Yamada

Fabian Gusovsky

Bruce Decosta

Makoto Kaino

Koji Yamada

Yoshinori Sakuma

Katsuhiro Moriya

Koichi Katayama

Mannen Mishima

Hiroshi Shirota

Toshikazu Shimizu

Hong Du

Yoshiharu Mizui

Hiromitsu Yokohama

Marc Pesant

Yukio Nishizawa

Ye Yao

Keizo Sato

Yoshinori Katoh

Yan (Janet) Zhao

Yumiko Nagasaka

Kensaku Kinoshita

Yoshikazu Kuboi

Tetsu Kawano

Masanori Fujita

Jesse Chow

Akifumi Kimura

Charles-André Lemelin

Lynda Tremblay

Hiroe Minami

Naoki Ozeki

Masahiro Yasuda

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.

Substituted liposaccharides useful in the treatment and prevention of endotoxemia

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.

Methods of reducing the severity of mucositis

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine Areceptor antagonism, preferably an adenosine Areceptor antagonism, or a salt thereof.

Medicinal compositions promoting bowel movement

The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is &#x2014;CHCH&#x2014;, or &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; Ris:(in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and Rand Rare the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; Ris an amino group, etc. which maybe substituted with a lower alkyl group, etc.; Ris a cycloalkyl group, an optionally substituted aryl group, etc.; and Ris a lower alkyl group etc.

Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I);(wherein Rrepresents e.g. an amino group which may be substituted with an alkyl group; Rrepresents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; Rrepresents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Nitrogen-containing tricyclic compounds and drugs containing the same

Heterocycle-containing carboxylic acid derivative and drug containing the same

Carboxylic acid derivatives having fused rings

Growing community of inventors

Belmont, MA, United States of America

Seiichi Kobayashi